Hematopoyetic and lymphoid tumors

Anna Sureda Balari

PRINCIPAL INVESTIGATORS
  • Concepcion Boque Genovart
  • Montserrat Arnan Sangerman
  • Santiago Mercadal Vilchez
  • Eva Domingo Domenech
  • Victoria Clapes Puig
  • Eva Gonzalez Barca
  • Monica Mansilla Suarez
  • Octavio Servitje Bedate
  • Sonia González Rodríguez
CLINICAL RESEARCHERS
  • Clara Maluquer Artigal
  • Alberto Mussetti
  • Anna Carla Oliveira Ramos
  • Sergio Cano Olivar
  • Nadia Garcia Lozano
POSTDOCTORAL RESEARCHERS
  • Maria Cristina Marin Monerris
PREDOCTORAL RESEARCHERS
  • Maria Cecilia Vilas
SCIENTIFIC SUPPORT
  • Beatriz Patiño Gutierrez
  • Rocio Parody Porras
MANAGEMENT SUPPORT
  • Miriam Ratia Garcia
  • Meriem Kara
  • Miriam Espinosa Leiva
  • Damir Emanuel Blazevic Limone
Cancer
Oncobell

Scientific production

70

PAPERS

Impact factor: 583,514

12 PUBLICATIONS IN FIRST DECILE

43 PUBLICATIONS IN FIRST QUARTILE

50 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau M, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, Elliott B, DeMarco D, Azaryan A, Chiu C, Li T, Chen KM, Ahmadi T, Lugtenburg PJ. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398(10306):1157-1169. doi:10.1016/S0140-6736(21)00889-8. IF:79,32.
  • Hutchings M, Morschhauser F, Iacoboni G, Carlo Stella C, Offner FC, Sureda A, Salles G, Martínez Lopez J, Crump M, Thomas DN, Morcos PN, Ferlini C, Bröske AE, Belousov A, Bacac M, Dimier N, Carlile DJ, Lundberg L, Perez Callejo D, Umaña P, Moore T, Weisser M, Dickinson MJ. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021;39(18):1959-1970. doi:10.1200/JCO.20.03175. IF:44,54.
  • Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar Company J, Ottaviani D, Chowdhury A, Merry E, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Liñan R, Rossi S, Carmona García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Saponara M, Cruz CA, García Illescas D, Felip E, Roqué Lloveras A, Sharkey R, Roldán E, Reyes R, Earnshaw I, Ferrante D, Marco Hernández J, Ruiz Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez Vila C, Sanchez de Torre A, Cantini L, Filetti M, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Van Hemelrijck M, Diamantis N, Newsom Davis T, Gennari A, Cortellini A, OnCovid study G. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol. 2021;22(12):1669-1680. doi:10.1016/S1470-2045(21)00573-8. IF:41,32.
  • Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hajek R, Illes A, Wrobel T, Sureda A, Beksac M, Goncalves IZ, Blade J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison Blanche P, Moreau P, San Miguel JF, Richardson PG. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021;22(1):142-154. doi:10.1016/S1470-2045(20)30680-X. IF:41,32.
  • Condom M, Climent F, Fernandez D, Colomer D, Lopez Guerra M, Varela M, Carro I, Maluquer C, Mercadal S, Oliveira AC, Pane M, Matias Guiu X, Gonzalez Barca E, Sureda A, Domingo Domenech E. Clonal relationship in multisited mucosa-associated lymphoid tissue lymphomas: a single-centre experience. Br J Haematol. 2021;A(6):1020-1025. doi:10.1111/bjh.16717. IF:7,00.

Research highlights

PROJECTS

4 Competitive projects
5 Non competitive projects
222 Clinical trials

PUBLISHED WORKS

2 Clinical guidelines

NETWORKS

AGAUR – GRE

Selected projects

  • 20CEE016. RESILIENCE: Remote Ischemic Conditioning in Lymphoma Patients Receiving Anthracyclines. (SEP-210653203). COMISSIÓ EUROPEA. 2021-2026. IP:GONZALEZ BARCA,EVA.
  • 21FIS043. Plataforma de Unidades de Investigación Clínica y Ensayos Clínicos. (PT20/00171). ISCIII. 2021-2023. IP:CLIMENT ESTELLER,FINA.
  • 19PSJ025. Improving outpatient follow-up after CAR T-cells therapy: patient real-time monitoring through wearable devices and QoL assessment performed with the use of a digital platform. (GLD19-00035). GILEAD SCIENCES, S.L.U. 2019-2023. IP:MUSSETTI,ALBERTO.
  • AEC21013. Preclinical and clinical assessment of universal cord blood iPSC-derived CAR-NK cells for “off-the-shelf” cancer immunotherapy. (PRYCO211297MADR). IP:SUREDA BALARI,ANA MARIA.
  • ACL:2022-026-1. Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study). (ATA129-EBV-302 (ALLELE Study)). ATARA BIOTHERAPEUTICS, INC. 2021IP:EVA GONZALEZ BARCA.